Robert D M Hadden1, Fabrizio Marreno2. 1. Consultant Neurologist and Honorary Senior Lecturer, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. 2. Specialist Nurse Department of Neurology, King's College Hospital, London, UK.
Abstract
OBJECTIVES: To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS: Eight consecutive patients, four with MMN and four with CIDP, already on long-term, hospital-based IVIG were switched to home-based SCIG. These patients were selected on the basis of their requirement for relatively low treatment doses, problems experienced with IVIG, and their willingness to switch to SCIG. RESULTS: After a mean 33 [standard deviation (SD) 19] months receiving SCIG, 7 patients remained neurologically stable and 6 remained on a similar mean weekly immunoglobulin dose relative to their original intravenous dose. A good outcome was reported by 7 of the 8 patients: there were improvements in nausea and headache (n = 4), need to travel to hospital (n = 4), venous access problems (n = 3), immunoglobulin-induced neutropenia (n = 3), treatment wearing-off fluctuations (n = 2), IVIG-induced allergy requiring antihistamine/hydrocortisone (n = 1) and time taken off work (n = 1). The eighth patient required increasing doses of immunoglobulin to maintain strength but still wanted to continue SCIG. Seven patients completed a questionnaire: there was a very high overall satisfaction level with immunoglobulin treatment [mean 96 (SD 5), visual analogue scale (VAS) where 0 = very unsatisfied, 100 = very satisfied]; and very strong preference for subcutaneous over intravenous immunoglobulin (VAS mean 93 [SD 12] where 0 = prefer IVIG, 100 = prefer SCIG). CONCLUSIONS: In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.
OBJECTIVES: To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS: Eight consecutive patients, four with MMN and four with CIDP, already on long-term, hospital-based IVIG were switched to home-based SCIG. These patients were selected on the basis of their requirement for relatively low treatment doses, problems experienced with IVIG, and their willingness to switch to SCIG. RESULTS: After a mean 33 [standard deviation (SD) 19] months receiving SCIG, 7 patients remained neurologically stable and 6 remained on a similar mean weekly immunoglobulin dose relative to their original intravenous dose. A good outcome was reported by 7 of the 8 patients: there were improvements in nausea and headache (n = 4), need to travel to hospital (n = 4), venous access problems (n = 3), immunoglobulin-induced neutropenia (n = 3), treatment wearing-off fluctuations (n = 2), IVIG-induced allergy requiring antihistamine/hydrocortisone (n = 1) and time taken off work (n = 1). The eighthpatient required increasing doses of immunoglobulin to maintain strength but still wanted to continue SCIG. Seven patients completed a questionnaire: there was a very high overall satisfaction level with immunoglobulin treatment [mean 96 (SD 5), visual analogue scale (VAS) where 0 = very unsatisfied, 100 = very satisfied]; and very strong preference for subcutaneous over intravenous immunoglobulin (VAS mean 93 [SD 12] where 0 = prefer IVIG, 100 = prefer SCIG). CONCLUSIONS: In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.
Authors: L H Markvardsen; J-C Debost; T Harbo; S H Sindrup; H Andersen; I Christiansen; M Otto; N K Olsen; L L Lassen; J Jakobsen Journal: Eur J Neurol Date: 2013-01-07 Impact factor: 6.089
Authors: Peter J Dyck; Christopher J Boes; Donald Mulder; Clark Millikan; Anthony J Windebank; P James B Dyck; Raul Espinosa Journal: J Peripher Nerv Syst Date: 2005-06 Impact factor: 3.494
Authors: Filip Eftimov; Marinus Vermeulen; Rob J de Haan; Leonard H van den Berg; Ivo N van Schaik Journal: J Peripher Nerv Syst Date: 2009-06 Impact factor: 3.494
Authors: Julia Zhu; Gretchen Ayer; Heather S Kirkham; Chi-Chang Chen; Rolin L Wade; Swapna U Karkare; Chester H Robson; Jordan S Orange Journal: J Res Pharm Pract Date: 2019 Apr-Jun
Authors: Ivo N van Schaik; Orell Mielke; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Billie L Durn; David R Cornblath; Ingemar S J Merkies Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-07-03
Authors: Ivo N van Schaik; Nan van Geloven; Vera Bril; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Orell Mielke; David R Cornblath; Ingemar S J Merkies Journal: Trials Date: 2016-07-25 Impact factor: 2.279
Authors: Ingrid J T Herraets; Jaap N E Bakers; Ruben P A van Eijk; H Stephan Goedee; W Ludo van der Pol; Leonard H van den Berg Journal: J Neurol Date: 2019-07-19 Impact factor: 4.849